Atlas Trials

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

Clinical trial NCT03593213 · TERMINATED

Trial details

NCT number
NCT03593213
Sponsor
AbbVie
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2018-07-30
Primary completion
2021-02-11
Enrollment
587

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.